Medimetriks Pharmaceuticals, Inc. is led by the key Senior Management Team of the former Bradley Pharmaceuticals, Inc.  The company’s mission is to develop, license and commercialize innovative prescription skincare brands that fill unmet needs in the Dermatology and Podiatry markets.  Medimetriks’ therapies treat conditions including acne, rosacea, seborrheic dermatitis, severe dry skin, dystrophic nails and impetigo.

The Medimetriks portfolio of prescription brands currently consists of six products – four internally developed brands that feature unique vehicles with natural ingredients; and two additional brands as the result of a licensing agreement with Perrigo Company.  All of our brands offer unique characteristics that set them apart in the marketplace.

Medimetriks brands are currently being promoted by a Field Sales Force that consists of approximately 20 professional representatives located in the most important markets in the Country, including New York, New Jersey, Pennsylvania, Tennessee, Georgia, Florida, Texas, North Carolina, Alabama, Illinois and Michigan.  The Company plans to aggressively expand its field force.

In June 2009, Medimetriks took steps toward building a robust patented portfolio through a licensing agreement with PharmaMar SA (Grupo Zeltia, ZEL.MC) for Kahalalide F, a novel depsipeptide extracted from the Hawaiian sea slug Elysia rufescens, which has been developed synthetically.  This new molecule will be developed for a possible psoriasis indication.
The Medimetriks Team continues to focus its commitment on creating a leading Dermatology and Podiatry Company. To ensure Medimetriks’ continuing success, the Company is dedicated to serving the physicians who support Medimetriks’ brands, the patients who utilize its therapies, the wholesalers and pharmacies who enable distribution and the stockholders and business partners whose support is critical to the Company’s future.

Officers

Bradley Glassman is the President and CEO of Medimetriks.  Previously, Mr. Glassman was Senior Vice President, Sales and Marketing of Bradley Pharmaceuticals.  During his tenure at Bradley, Mr. Glassman also served as Vice President, Sales and Marketing, Vice President, Marketing and Director of Corporate Development. Mr. Glassman received his B.A. and M.B.A. from Tulane University.

R. Brent Lenczycki, CPA,is Medimetriks’ Chief Financial Officer.  Prior to joining Medimetriks, Mr. Lenczycki served as Vice President, Chief Financial Officer of Bradley Pharmaceuticals.  During his time at Bradley, Mr. Lenczycki also held the positions of Manager of Finance and Purchasing and Vice President, Finance. From 1995 to 1998, Mr. Lenczycki held positions in public accounting at Arthur Andersen LLP, and prior to 1995, as an internal auditor for Harrah’s Hotel and Casino. Mr. Lenczycki received his B.S. from St. Joseph’s University and his M.B.A. from Tulane University. 

Alan Goldstein is the Executive Vice President, Business Development for Medimetriks. Mr. Goldstein served as Vice President, Corporate Development at Bradley Pharmaceuticals. Prior to joining Bradley, Mr. Goldstein served as Counsel in the corporate department of the international law firm of Kaye Scholer LLP from November 2000 to May 2002. Previously, Mr. Goldstein was a partner in the New York law firms of Winick & Rich, P.C. and Reid & Priest LLP and worked as an associate at that firm and one of its predecessors, Spengler Carlson Gubar Brodsky & Frischling. Mr. Goldstein received his B.A. from the University of Michigan and his J.D. from the University of Pittsburgh. 

David Addis is the Senior Vice President of Brand Communication for Medimetriks.  At Bradley, Mr. Addis served as Vice President of Creative Services and was responsible for the Company’s advertising, marketing and corporate communications.  Prior to this office, Mr. Addis served as Director of Creative Services.  Previously, Mr. Addis was a Principal at Polan & Waski, LLC, a leading brand identity and marketing communication firm.  Mr. Addis received his B.A. from Dartmouth College.